Substrate Mapping and Ablation in Sinus rhythm to Halt Ventricular Tachycardia

Beth Israel - Deaconess Hospital (USA)0 个研究点目标入组 128 人开始时间: 2006年9月25日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•Men and women who were at least 18 years old were eligible for the study if they had a history of an MI as documented by an electrocardiogram or cardiac imaging and had a planned or recent (within six months) implantation of an ICD for either:
•1. Ventricular Fibrillation (VF) arrest
•2. Hemodynamically-unstable Ventricular Tachycardia (VT)
•3. Syncope and inducible VT during invasive electrophysiologic testing (for this group, syncope is assumed to be the qualifying spontaneous arrhythmic event)
•4. Patients who had received an ICD for primary prophylaxis and then experienced a single appropriate ICD therapy

•1. Treated with a Class I/III antiarrhythmic drug
•2. The substrate for the ventricular arrhythmia was thought not to be due to the myocardial infarction
•3. Active ongoing cardiac ischemia was felt to be the cause of the ventricular arrhythmia;
•4. Incessant or multiple VT episodes necessitating some form of treatment ? drugs or ablation
•5. Unable to give informed consent
•6. If the patient had experienced a stroke within 30 days
•7. Contraindication to anticoagulation
•8. Any medical/non-medical condition likely to prevent completion of the trial

发起方

Beth Israel - Deaconess Hospital (USA)